In an open-label trial of 59 adults with moderate chronic rhinosinusitis with nasal polyps and mild-to-moderate IgE-mediated asthma, omalizumab plus standard therapy reduced Nasal Polyp Score over 12 months vs standard therapy alone; asthma control also improved.
RCTn = 59
Bożek et al. Efficacy of omalizumab in moderate chronic rhinosinusitis with nasal polyps and IgE-mediated asthma